Metabolic Disorders: when insurers say no, reviewers often say yes

Where the denial was overturned

Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for suction assisted lipectomy surgery on: upper extremity RT, upper extremity LT, trunk RT, trunk LT, and lower extremity. Per the medical records, the patient’s disease has progressed to stage 4 with secondary lymphedema, representing the most advanced stage, where functional limitations are most pronounced and surgical intervention offers the greatest benefit.

Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for lipectomy of the lower extremities involving the ankles, calves, thighs, and knees.The records support that this patient meets diagnostic criteria for lipedema, stage 1, with predominant lower extremity involvement and minimal upper extremity involvement. The condition is painful, functionally limiting, and refractory to conservative therapy. The patient demonstrates disproportionate adipose tissue hypertrophy of the lower extremities relative to the trunk. The records additionally indicate that the abnormal adipose tissue has not responded to caloric restriction, exercise, or bariatric interventions.

Where the denial was upheld

Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Leqvio. The records document that this patient presents with a history of hyperlipidemia with markedly elevated low-density lipoprotein (LDL) cholesterol and an elevated coronary artery calcium score (CACS). The patient has reportedly been unable to tolerate treatment with statins. The patient’s provider has recommended treatment with Leqvio. Leqvio is a hyperlipidemia therapy directed against PCSK9, although it is a different type of medication than other medications commonly used for the same purpose, such as Repatha or Praluent, which are monoclonal antibody medications.

Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Vascepa (icosapent ethyl).The records document that this patient has a history of diabetes mellitus, hyperlipidemia, including hypertriglyceridemia, and elevated apolipoprotein B. There is no documentation of a prior clinical cardiovascular event. Coronary artery calcium scoring suggests atherosclerotic cardiovascular disease risk, and overall cardiovascular risk is elevated. The most recent lipid panel shows significantly elevated low-density lipoprotein cholesterol in the setting of diabetes mellitus, supporting the need for aggressive lipid-lowering therapy.The patient has not tolerated statin therapy due to myalgias.

These outcomes come from California’s external review program — an independent physician panel whose decision binds the insurer. Every state has an equivalent, and internal appeals succeed even more often. If your care for metabolic disorders was denied, the published record says the denial is worth fighting.